Víctor Castro-Urda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Víctor Castro-Urda has a total of 386 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Fernández Lozano
Hospital Universitario Puerta de Hierro, Majadahonda, Spain
23 shared publications Jorge Toquero-Ramos
7 shared publications- Diego Jiménez-Sánchez
Electrophysiology Unit (V.C.-U., M.S.-D., D.J.-S., C.A.-A., P.V.-M., A.L.-R., D.G.-R., D.S.-O., C.P.-T., E.G.-I., J.T.-R., I.F.-L.), Cardiology Service, Hospital Electrophysiology Unit Puerta de Hierro, Madrid, Spain
4 shared publications - Eusebio García-Izquierdo
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
4 shared publications - Jorge Toquero Ramos
Puerta de Hierro Universitary hospital Madrid Comunidad de Madrid Spain
4 shared publications - Josep Brugada
Arrhythmia Section, Department of Cardiology, Institut Clínic Cardiovascular (ICCV), Hospital Clínic de Barcelona, Universitat de Barcelona & Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalunya, Spain (I.R.-L, P.G., S.V.-C., J.T.O-P, J.-B.G., M.R.-C., E.G., J.-M.T., E.A., P.S.-S., L.Q., R.B., R.D., M.N., J.B., L.M., A.P.-S.).
4 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Predictors of Success in Fractured Electrode Extraction: The Impact of Fracture Location and Access Strategies
Introduction: Fractured or sheared cardiac implantable electronic device leads presents a unique clinical challenge in transvenous lead extraction. These cases are associated with clinical failure rates of up to 40% and a greater likelihood of retained fragments. The aim of this study was to characterize fractured lead extractions performed at a referral center and identify predictors of complete removal and clinical success. Methods: We conducted a retrospective single center study including all consecutive patients who underwent TLE for electrodes fractured before or during extraction between October 2011 and December 2025. Clinical, echocardiographic, and procedural data were collected. Results: A total of 46 procedures were analyzed. Mean age was 62.7 years and median lead dwell time was 9.0 years. The most frequent fracture site was the electrode body (67.4%). A rotational mechanical sheath was used in 84.8% of cases (39/46), and femoral snaring was used in 60.8%. Complete extraction occurred in 32.6% whereas clinical success was achieved in 80.4% of patients. Retained fragments > 4 cm were observed in 28.3%. In multivariate analysis, the use of a 13Fr sheath was independently associated with lower odds of clinical success ( p = 0.011). Fracture location was the only consistent independent predictor of complete extraction ( p = 0.031). Femoral access showed a favorable trend but did not reach statistical significance after adjustment. Conclusions: In fractured lead extraction, fracture location is the strongest predictor of complete removal, surpassing clinical and procedural variables. These findings highlight the importance of preoperative planning and suggest that femoral access may play a key role in selected complex cases.
- 9 November 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Predictors of Success in Fractured Electrode Extraction: The Impact of Fracture Location and Access Strategies
Introduction: Fractured or sheared cardiac implantable electronic device leads presents a unique clinical challenge in transvenous lead extraction. These cases are associated with clinical failure rates of up to 40% and a greater likelihood of retained fragments. The aim of this study was to characterize fractured lead extractions performed at a referral center and identify predictors of complete removal and clinical success. Methods: We conducted a retrospective single center study including all consecutive patients who underwent TLE for electrodes fractured before or during extraction between October 2011 and December 2025. Clinical, echocardiographic, and procedural data were collected. Results: A total of 46 procedures were analyzed. Mean age was 62.7 years and median lead dwell time was 9.0 years. The most frequent fracture site was the electrode body (67.4%). A rotational mechanical sheath was used in 84.8% of cases (39/46), and femoral snaring was used in 60.8%. Complete extraction occurred in 32.6% whereas clinical success was achieved in 80.4% of patients. Retained fragments > 4 cm were observed in 28.3%. In multivariate analysis, the use of a 13Fr sheath was independently associated with lower odds of clinical success ( p = 0.011). Fracture location was the only consistent independent predictor of complete extraction ( p = 0.031). Femoral access showed a favorable trend but did not reach statistical significance after adjustment. Conclusions: In fractured lead extraction, fracture location is the strongest predictor of complete removal, surpassing clinical and procedural variables. These findings highlight the importance of preoperative planning and suggest that femoral access may play a key role in selected complex cases.
- Top Cited PapersOpen Access
- 2 July 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Safety and efficacy of a lattice-tip catheter for ventricular arrhythmia ablation: the AFFERA Ventricular Arrhythmia Ablation Registry (AVAAR)
Aims: The feasibility and safety of the lattice-tip catheter for ventricular arrhythmia (VA) ablation in humans remain largely unknown. This study aimed to assess feasibility, safety profile as well as patient outcomes after VA ablation with a lattice-tip catheter in a multicentre European registry. Methods and results: All 18 European centres using the AFFERA system in September 2024 agreed to participate. Clinical, procedural, and follow-up data (minimum 3 months) were systematically collected and analysed. A total of 126 patients (18% female; mean age 59 ± 16 years) underwent VA ablation using the lattice-tip catheter during the inclusion period. Ablation indications included ventricular tachycardia (VT) in 99, premature ventricular complexes (PVCs) in 23, and ventricular fibrillation (VF) in 4 patients. Major and minor acute complications were observed in 7 (6%) and 18 (14%) procedures, respectively. They included thrombo-embolic event (n = 2), major bleeding (n = 2), ventricular fibrillation induction (n = 1), tamponade due to epicardial access (n = 1), and cardiogenic shock due to prolonged VT mapping (n = 1). Within the first month post-procedure, three patients died [from multi-organ failure (n = 2) and sepsis (n = 1)], two had worsening heart failure, one myocardial infarction, one sepsis, and one major gastro-intestinal bleeding. After a mean follow-up of 5.6 ± 3.7 months, absence of recurrence was 78% for PVC, 70% for VT, and 100% for VF. Conclusion: In this complex population with refractory VA, ablation using the lattice-tip catheter appears feasible and relatively safe. In the absence of large, randomized trials, exhaustive registry is of key importance to ensure safety and efficacy of new catheter technologies.
- 2 July 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Top Cited PapersOpen AccessSafety and efficacy of a lattice-tip catheter for ventricular arrhythmia ablation: the AFFERA Ventricular Arrhythmia Ablation Registry (AVAAR)
Aims: The feasibility and safety of the lattice-tip catheter for ventricular arrhythmia (VA) ablation in humans remain largely unknown. This study aimed to assess feasibility, safety profile as well as patient outcomes after VA ablation with a lattice-tip catheter in a multicentre European registry. Methods and results: All 18 European centres using the AFFERA system in September 2024 agreed to participate. Clinical, procedural, and follow-up data (minimum 3 months) were systematically collected and analysed. A total of 126 patients (18% female; mean age 59 ± 16 years) underwent VA ablation using the lattice-tip catheter during the inclusion period. Ablation indications included ventricular tachycardia (VT) in 99, premature ventricular complexes (PVCs) in 23, and ventricular fibrillation (VF) in 4 patients. Major and minor acute complications were observed in 7 (6%) and 18 (14%) procedures, respectively. They included thrombo-embolic event (n = 2), major bleeding (n = 2), ventricular fibrillation induction (n = 1), tamponade due to epicardial access (n = 1), and cardiogenic shock due to prolonged VT mapping (n = 1). Within the first month post-procedure, three patients died [from multi-organ failure (n = 2) and sepsis (n = 1)], two had worsening heart failure, one myocardial infarction, one sepsis, and one major gastro-intestinal bleeding. After a mean follow-up of 5.6 ± 3.7 months, absence of recurrence was 78% for PVC, 70% for VT, and 100% for VF. Conclusion: In this complex population with refractory VA, ablation using the lattice-tip catheter appears feasible and relatively safe. In the absence of large, randomized trials, exhaustive registry is of key importance to ensure safety and efficacy of new catheter technologies.
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (1) , e012917
Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial
BACKGROUND: Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development. METHODS: We investigated the efficacy and safety of combining cryoballoon pulmonary vein isolation (PVI) with SVC ablation compared with PVI alone in 100 patients with paroxysmal or non–long-standing persistent atrial fibrillation. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. Each patient was given a mobile device to record a daily ECG and detect atrial tachyarrhythmias. RESULTS: The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 days post-catheter ablation, did not significantly differ between the 2 groups (62.9% versus 72%; P =0.41). However, the PVI+SVC group exhibited higher rates of phrenic nerve paralysis (20.8% versus 6%; P =0.003) and transient sinus node injury (18.8% versus 0%; P =0.001) compared with the PVI-only group. The median burden of atrial tachyarrhythmia showed no significant difference ( P =0.91). CONCLUSIONS: The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. These findings do not support the routine inclusion of SVC ablation in cryoballoon procedures for first-time catheter ablation in patients with paroxysmal or non–long-standing persistent atrial fibrillation.
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (1) , e012917
Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial
BACKGROUND: Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development. METHODS: We investigated the efficacy and safety of combining cryoballoon pulmonary vein isolation (PVI) with SVC ablation compared with PVI alone in 100 patients with paroxysmal or non–long-standing persistent atrial fibrillation. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. Each patient was given a mobile device to record a daily ECG and detect atrial tachyarrhythmias. RESULTS: The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 days post-catheter ablation, did not significantly differ between the 2 groups (62.9% versus 72%; P =0.41). However, the PVI+SVC group exhibited higher rates of phrenic nerve paralysis (20.8% versus 6%; P =0.003) and transient sinus node injury (18.8% versus 0%; P =0.001) compared with the PVI-only group. The median burden of atrial tachyarrhythmia showed no significant difference ( P =0.91). CONCLUSIONS: The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. These findings do not support the routine inclusion of SVC ablation in cryoballoon procedures for first-time catheter ablation in patients with paroxysmal or non–long-standing persistent atrial fibrillation.
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (12) , e013145
Electrophysiological Phenotype-Genotype Study of Sustained Monomorphic Ventricular Tachycardia in Inherited, High Arrhythmic Risk, Left Ventricular Cardiomyopathy
BACKGROUND: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes. METHODS: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers. Electrophysiological study, imaging, and outcomes data after ablation were assessed in relation to genotype. RESULTS: Seventy-one patients were included (49.6 Q1–Q3 [40–60] years, 76% men). They were divided into 4 groups according to the affected protein: desmosomal ( DSP , PKP2 , DSG2 , and DSC2 ), nuclear membrane ( LMNA and TMEM43 ), cytoskeleton ( FLNC and DES ), and sarcoplasmic reticulum ( PLN ). Desmosomal genes, TMEM43 , and PLN were associated with biventricular disease, while variants in LMNA and cytoskeleton genes had predominant left ventricle involvement ( P =0.001). The location of the clinical-SMVT substrate was significantly different based on genotype ( P =0.005). DSP and cytoskeleton genes presented SMVTs with right bundle branch block morphology, which origin was identified in the inferolateral segments of the left ventricle. The other desmosomal genes ( PKP2 and DSG2 ), along with TMEM43 , showed SMVTs with left bundle branch block morphology and predominantly right ventricular substrate. In contrast, LMNA substrate was mainly observed in the interventricular septum. During a median of 26 Q1–Q3 (10.6–65) months, 27% of patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016). Nuclear membrane genes demonstrated the highest recurrence rate compared with desmosomal genes (hazard ratio, 4.56 [95% CI, 1.5–13.8]). CONCLUSIONS: The anatomic substrate of SMVTs shows a strong correlation with the underlying genotype, electrocardiographic morphology, and recurrence rate. Particularly, patients with nuclear membrane gene variants have a significantly higher recurrence rate compared with those with desmosomal gene variants.
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (12) , e013145
Electrophysiological Phenotype-Genotype Study of Sustained Monomorphic Ventricular Tachycardia in Inherited, High Arrhythmic Risk, Left Ventricular Cardiomyopathy
BACKGROUND: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes. METHODS: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers. Electrophysiological study, imaging, and outcomes data after ablation were assessed in relation to genotype. RESULTS: Seventy-one patients were included (49.6 Q1–Q3 [40–60] years, 76% men). They were divided into 4 groups according to the affected protein: desmosomal ( DSP , PKP2 , DSG2 , and DSC2 ), nuclear membrane ( LMNA and TMEM43 ), cytoskeleton ( FLNC and DES ), and sarcoplasmic reticulum ( PLN ). Desmosomal genes, TMEM43 , and PLN were associated with biventricular disease, while variants in LMNA and cytoskeleton genes had predominant left ventricle involvement ( P =0.001). The location of the clinical-SMVT substrate was significantly different based on genotype ( P =0.005). DSP and cytoskeleton genes presented SMVTs with right bundle branch block morphology, which origin was identified in the inferolateral segments of the left ventricle. The other desmosomal genes ( PKP2 and DSG2 ), along with TMEM43 , showed SMVTs with left bundle branch block morphology and predominantly right ventricular substrate. In contrast, LMNA substrate was mainly observed in the interventricular septum. During a median of 26 Q1–Q3 (10.6–65) months, 27% of patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016). Nuclear membrane genes demonstrated the highest recurrence rate compared with desmosomal genes (hazard ratio, 4.56 [95% CI, 1.5–13.8]). CONCLUSIONS: The anatomic substrate of SMVTs shows a strong correlation with the underlying genotype, electrocardiographic morphology, and recurrence rate. Particularly, patients with nuclear membrane gene variants have a significantly higher recurrence rate compared with those with desmosomal gene variants.
- 25 July 2024
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 77 (12) , 1058-1059
Charting the path: from the defibrillator vest to a reborn heart
- 25 July 2024
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 77 (12) , 1058-1059
Charting the path: from the defibrillator vest to a reborn heart
- Open Access
- 1 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1173
Right Bundle Branch Block Predicts Appropriate Implantable Cardioverter Defibrillator Therapies in Patients with Non-Ischemic Dilated Cardiomyopathy and a Prophylactic Implantable Cardioverter Defibrillator
Background: The benefit of prophylactic implantable cardioverter defibrillators (ICDs) in patients with severe systolic dysfunction of non-ischemic origin is still unclear, and the identification of patients at risk for sudden cardiac death remains a major challenge. Aims/Methods: We retrospectively reviewed all consecutive patients with non-ischemic dilated cardiomyopathy (NICM) who underwent prophylactic ICD implantation between 2008 and 2020 in two tertiary centers. Our main goal was to identify the predictors of appropriate ICD therapies (anti-tachycardia pacing [ATP] and/or shocks) in this cohort of patients. Results: A total of 224 patients were included. After a median follow-up of 51 months, 61 patients (27.2%) required appropriate ICD therapies. Patients with appropriate ICD therapies were more frequently men (87% vs. 69%, p = 0.006), of younger age (59 years, (53–65) vs. 64 years, (57–70); p = 0.02), showed more right bundle branch blocks (RBBBs) (15% vs. 4%, p = 0.007) and less left bundle branch blocks (LBBBs) (26% vs. 47%, p = 0.005) in the ECG, and had higher left ventricular end-diastolic (100 mL/m2, (90–117) vs. 86, (71–110); p = 0.011) and systolic volumes (72 mL/m2, (59–87) vs. 61, (47–81), p = 0.05). In a multivariate competing-risks regression analysis, RBBB (HR 2.26, CI 95% 1.02–4.98, p = 0.043) was identified as an independent predictor of appropriate ICD therapies. Conclusion: RBBBs may help to identify patients with NICM at high risk of ventricular arrhythmias and requiring ICD intervention.
- 1 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1173
Open AccessRight Bundle Branch Block Predicts Appropriate Implantable Cardioverter Defibrillator Therapies in Patients with Non-Ischemic Dilated Cardiomyopathy and a Prophylactic Implantable Cardioverter Defibrillator
Background: The benefit of prophylactic implantable cardioverter defibrillators (ICDs) in patients with severe systolic dysfunction of non-ischemic origin is still unclear, and the identification of patients at risk for sudden cardiac death remains a major challenge. Aims/Methods: We retrospectively reviewed all consecutive patients with non-ischemic dilated cardiomyopathy (NICM) who underwent prophylactic ICD implantation between 2008 and 2020 in two tertiary centers. Our main goal was to identify the predictors of appropriate ICD therapies (anti-tachycardia pacing [ATP] and/or shocks) in this cohort of patients. Results: A total of 224 patients were included. After a median follow-up of 51 months, 61 patients (27.2%) required appropriate ICD therapies. Patients with appropriate ICD therapies were more frequently men (87% vs. 69%, p = 0.006), of younger age (59 years, (53–65) vs. 64 years, (57–70); p = 0.02), showed more right bundle branch blocks (RBBBs) (15% vs. 4%, p = 0.007) and less left bundle branch blocks (LBBBs) (26% vs. 47%, p = 0.005) in the ECG, and had higher left ventricular end-diastolic (100 mL/m2, (90–117) vs. 86, (71–110); p = 0.011) and systolic volumes (72 mL/m2, (59–87) vs. 61, (47–81), p = 0.05). In a multivariate competing-risks regression analysis, RBBB (HR 2.26, CI 95% 1.02–4.98, p = 0.043) was identified as an independent predictor of appropriate ICD therapies. Conclusion: RBBBs may help to identify patients with NICM at high risk of ventricular arrhythmias and requiring ICD intervention.
- 10 May 2024
- Published by Morressier GmbH
Impact of upgrading to cardiac resynchronization therapy or left bundle branch pacing in patients with ATTR cardiomyopathy PC67 (#389)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Impact of upgrading to cardiac resynchronization therapy or left bundle branch pacing in patients with ATTR cardiomyopathy PC67 (#389)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 6 December 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (1) , 149-155
Feasibility and safety of left bundle branch area pacing in cardiac amyloidosis. A single center experience
BackgroundConventional right ventricle (RV) pacemaker stimulation has been associated with worse clinical outcomes in patients with cardiac amyloidosis (CA). Left bundle branch area pacing (LABPP) has been suggested as a promising alternative. We sought to assess the safety, feasibility, and outcomes of LABPP in patients with CA.MethodsWe retrospectively analyzed echocardiography and pacing parameters and clinical outcomes in 23 consecutive patients with CA and LBBAP implanted from June 2020 to October 2022.ResultsLBBAP was successfully performed in 22 over 23 patients (19 male, 78.6 +/- 11.7 years, 20 ATTR, mean LVEF 45.5 +/- 16.2%). After the procedure, 9 patients showed Qr pattern and 11 a qR pattern in V1 on ECG. Average procedure time was 67 +/- 28 min. After 7.7 +/- 5.2 months follow-up, no procedure-related complications had occurred. Although, a significant reduction in QRS width (p = .001) was achieved, we did not observe significant changes in LVEF and Nt ProBNP at 6 months of follow-up. Pacing parameters were stable during follow-up: LBB capture threshold and R wave amplitude were 1.0 +/- 0.5 V and 10.6 +/- 6.0 mV versus 0.8 +/- 0.1 V, p = .21 and 10.6 +/- 5.1 mV (p = .985) at follow up.ConclusionLBBAP is safe and feasible pacing technique for patients with CA. LBBAP is associated with significant narrowing of QRSd without worsening in LVEF and Nt-proBNP.
- 6 December 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (1) , 149-155
Feasibility and safety of left bundle branch area pacing in cardiac amyloidosis. A single center experience
BackgroundConventional right ventricle (RV) pacemaker stimulation has been associated with worse clinical outcomes in patients with cardiac amyloidosis (CA). Left bundle branch area pacing (LABPP) has been suggested as a promising alternative. We sought to assess the safety, feasibility, and outcomes of LABPP in patients with CA.MethodsWe retrospectively analyzed echocardiography and pacing parameters and clinical outcomes in 23 consecutive patients with CA and LBBAP implanted from June 2020 to October 2022.ResultsLBBAP was successfully performed in 22 over 23 patients (19 male, 78.6 +/- 11.7 years, 20 ATTR, mean LVEF 45.5 +/- 16.2%). After the procedure, 9 patients showed Qr pattern and 11 a qR pattern in V1 on ECG. Average procedure time was 67 +/- 28 min. After 7.7 +/- 5.2 months follow-up, no procedure-related complications had occurred. Although, a significant reduction in QRS width (p = .001) was achieved, we did not observe significant changes in LVEF and Nt ProBNP at 6 months of follow-up. Pacing parameters were stable during follow-up: LBB capture threshold and R wave amplitude were 1.0 +/- 0.5 V and 10.6 +/- 6.0 mV versus 0.8 +/- 0.1 V, p = .21 and 10.6 +/- 5.1 mV (p = .985) at follow up.ConclusionLBBAP is safe and feasible pacing technique for patients with CA. LBBAP is associated with significant narrowing of QRSd without worsening in LVEF and Nt-proBNP.
- 11 September 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (10) , 1278-1286
Experience and insights from a prolonged electrocardiographic monitorization with a wearable system after an embolic stroke of unknown source
Embolic cerebrovascular events that remain of unknown etiology after a thorough diagnostic evaluation, are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) represents a significant underlying cause of ESUS. Our aims were to examine the overall diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Additionally, to evaluate the frequency of unexpected arrhythmic events (UAE) and their prognostic implications. We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 s, between 2017 and 2021. UAE were defined as arrhythmia events that were not correlated to the main reason of prolonged cardiac monitoring. AF was detected in 21 patients (10.5%). Patients with AF had more left atrial enlargement (OR = 4.22 [1.59-6.85]; p = .01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR = 5.73 [2.03-16.49]; p = .001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs. 10.3%; p = .002). Fifty three patients (26.5%) had UAE during PCMw. In six of them these findings led to targeted treatment. PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients. UAE were common, but did not impact prognosis.
- 11 September 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (10) , 1278-1286
Experience and insights from a prolonged electrocardiographic monitorization with a wearable system after an embolic stroke of unknown source
Embolic cerebrovascular events that remain of unknown etiology after a thorough diagnostic evaluation, are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) represents a significant underlying cause of ESUS. Our aims were to examine the overall diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Additionally, to evaluate the frequency of unexpected arrhythmic events (UAE) and their prognostic implications. We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 s, between 2017 and 2021. UAE were defined as arrhythmia events that were not correlated to the main reason of prolonged cardiac monitoring. AF was detected in 21 patients (10.5%). Patients with AF had more left atrial enlargement (OR = 4.22 [1.59-6.85]; p = .01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR = 5.73 [2.03-16.49]; p = .001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs. 10.3%; p = .002). Fifty three patients (26.5%) had UAE during PCMw. In six of them these findings led to targeted treatment. PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients. UAE were common, but did not impact prognosis.
- Open Access
- 24 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (Supplement)
Prolonged electrocardiographic monitorization with a wearable system after an embolic stroke of undetermined source
Funding Acknowledgements: Type of funding sources: None. Background: Embolic cerebrovascular events that remain of unknown etiology after careful diagnostic evaluation are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) is an important cause of ESUS. Purpose: Our aims were to analyze the global diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Methods: We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 seconds, between 2017-2021. Results: AF was detected in 21 patients (10,5 %). Patients with AF had more left atrial enlargement (OR=4,22 [1.59-6.85]; p=0.01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR=5,73 [2.03-16,49]; p=0.001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs 10,3%; p=0,002). Conclusion: PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients.
- 24 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (Supplement)
Open AccessProlonged electrocardiographic monitorization with a wearable system after an embolic stroke of undetermined source
Funding Acknowledgements: Type of funding sources: None. Background: Embolic cerebrovascular events that remain of unknown etiology after careful diagnostic evaluation are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) is an important cause of ESUS. Purpose: Our aims were to analyze the global diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Methods: We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 seconds, between 2017-2021. Results: AF was detected in 21 patients (10,5 %). Patients with AF had more left atrial enlargement (OR=4,22 [1.59-6.85]; p=0.01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR=5,73 [2.03-16,49]; p=0.001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs 10,3%; p=0,002). Conclusion: PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients.